Symbolbild · KI-generiert
Marvel Biosciences Corp.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Marvel Biosciences Corp., through its wholly owned subsidiary Marvel Biotechnology Inc., is a Calgary-based biotechnology company developing new treatments for neurological diseases and neurodevelopmental disorders. Our lead drug candidate, MB-204, is a novel fluorinated derivative version of Istradefylline, an approved Parkinson's drug and the only adenosine A2A receptor blocker currently on the market. Research shows that blocking the A2A receptor may help treat conditions such as autism, depression, and Alzheimer's disease. Marvel is also exploring MB-204's potential in rare disorders like Rett syndrome and Fragile X syndrome, aiming to bring new options to patients with few effective treatments.
Company description as published by the issuer via TMX Money.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Marvel Biosciences Corp. | MRVL | TSXV | 7 Mio. USD |
| LIR Life Sciences Corp. | SKNY | CSE | 7 Mio. USD |
| Red White & Bloom Brands Inc. | RWB | CSE | 7 Mio. USD |
| PreveCeutical Medical Inc. | PREV | CSE | 7 Mio. USD |
| Avant Brands Inc. | AVNT | TSX | 6 Mio. USD |
| Revive Therapeutics Ltd. | RVV | CSE | 7 Mio. USD |
| Captiva Verde Wellness Corp. | PWR | CSE | 8 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.